Compare Stocks: ALEC, OLMA, DSGN, and SANA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.14	$1.93	$1.09 ▼ $3.40	$238.95M	0.65	1.31 million shs	4.70 million shs
DSGN Design Therapeutics	$14.63 -1.1%	$14.12	$5.28 ▼ $17.25	$926.21M	1.66	575,188 shs	715,231 shs
OLMA Olema Pharmaceuticals	$10.22 -4.4%	$11.24	$6.65 ▼ $36.26	$935.35M	1.98	812,407 shs	922,990 shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$925.03M	2.12	2.92 million shs	3.28 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-13.01%	-0.47%	+39.87%	-24.65%
DSGN Design Therapeutics	-1.15%	-3.37%	-0.20%	+33.36%	+138.66%
OLMA Olema Pharmaceuticals	-4.40%	-4.93%	-2.11%	+3.55%	+30.86%
SANA Sana Biotechnology	+1.29%	-18.70%	-16.98%	+16.79%	+7.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.14	$1.93	$1.09 ▼ $3.40	$238.95M	0.65	1.31 million shs	4.70 million shs
DSGN Design Therapeutics	$14.63 -1.1%	$14.12	$5.28 ▼ $17.25	$926.21M	1.66	575,188 shs	715,231 shs
OLMA Olema Pharmaceuticals	$10.22 -4.4%	$11.24	$6.65 ▼ $36.26	$935.35M	1.98	812,407 shs	922,990 shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$925.03M	2.12	2.92 million shs	3.28 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-13.01%	-0.47%	+39.87%	-24.65%
DSGN Design Therapeutics	-1.15%	-3.37%	-0.20%	+33.36%	+138.66%
OLMA Olema Pharmaceuticals	-4.40%	-4.93%	-2.11%	+3.55%	+30.86%
SANA Sana Biotechnology	+1.29%	-18.70%	-16.98%	+16.79%	+7.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	69.39% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	12.78% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$42.40	314.87% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	198.19% Upside

Current Analyst Ratings Breakdown

Latest ALEC, OLMA, DSGN, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
8/13/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/23/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$13.86M	17.24	N/A	N/A	$0.28 per share	7.64
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	11/5/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest ALEC, OLMA, DSGN, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
DSGN Design Therapeutics	N/A	18.86	18.86
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
DSGN Design Therapeutics	56.64%
OLMA Olema Pharmaceuticals	91.78%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
DSGN Design Therapeutics	17.10%
OLMA Olema Pharmaceuticals	12.56%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	111.66 million	102.39 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable

ALEC, OLMA, DSGN, and SANA Headlines

Recent News About These Companies

Sana Biotechnology出席富国银行医疗健康大会：两大核心项目即将进入临床阶段

September 10 at 9:07 PM | cn.investing.com

Sana Biotechnology出席花旗2026年生物医药返校峰会：押注糖尿病疗法

September 10 at 9:07 PM | cn.investing.com

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10 at 5:00 PM | seekingalpha.com

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10 at 4:06 PM | seekingalpha.com

Bank of New York Mellon Corp Invests $1.67 Million in Sana Biotechnology, Inc. $SANA

September 9 at 3:43 AM | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.9% - What's Next?

September 8, 2026 | marketbeat.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

September 7, 2026 | prnewswire.com

Corient Private Wealth LP Invests $2.19 Million in Sana Biotechnology, Inc. $SANA

September 3, 2026 | marketbeat.com

Sana Biotechnology to Present at September 2026 Investor Conferences

September 1, 2026 | globenewswire.com

16,675,173 Shares in Sana Biotechnology, Inc. $SANA Acquired by BlackRock Inc.

September 1, 2026 | marketbeat.com

Canada Pension Plan Investment Board Purchases Shares of 10,218,400 Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Stake in Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

As U.S.-China biotech race heats up, Seattle makes its case to D.C.

August 27, 2026 | msn.com

As US.-China biotech race heats up, Seattle makes its case to DC

August 27, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7% After Analyst Upgrade

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Bank of America Corp DE Has $8.49 Million Stock Position in Sana Biotechnology, Inc. $SANA

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention

August 21, 2026 | kalkinemedia.comK

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts

August 21, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?

August 20, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% - Still a Buy?

August 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, OLMA, DSGN, and SANA Company Descriptions

Alector NASDAQ:ALEC

$2.14 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.13 -0.01 (-0.47%)

As of 09/11/2026 07:30 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Design Therapeutics NASDAQ:DSGN

$14.63 -0.17 (-1.15%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$14.64 +0.01 (+0.07%)

As of 09/11/2026 06:42 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Olema Pharmaceuticals NASDAQ:OLMA

$10.22 -0.47 (-4.40%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.82 -1.40 (-13.69%)

As of 09/11/2026 07:59 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Sana Biotechnology NASDAQ:SANA

$3.13 +0.04 (+1.29%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.15 +0.02 (+0.64%)

As of 09/11/2026 07:56 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, OLMA, DSGN, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, OLMA, DSGN, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, OLMA, DSGN, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, OLMA, DSGN, and SANA Company Descriptions

Alector NASDAQ:ALEC

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, OLMA, DSGN, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, OLMA, DSGN, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, OLMA, DSGN, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, OLMA, DSGN, and SANA Company Descriptions

Alector NASDAQ:ALEC

Design Therapeutics NASDAQ:DSGN

Olema Pharmaceuticals NASDAQ:OLMA

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools